ProJenX completes enrollment for Phase 1b trial of ALS drug Prosetin (opens in new tab)

ProJenX provided a development update for Prosetin, reporting that Pro-101, its Phase 1b study in people with amyotrophic lateral sclerosis, is fully enrolled. According to the company, interim data from the multiple ascending dose (MAD) portion, which included 41 participants across five dose levels, indicate Prosetin was generally safe and well tolerated with no Prosetin-related […] The post appeared first on <a href="